Key Takeaways
- Shares of Foghorn Therapeutics plummeted 49% to $1.84 following Eli Lilly’s decision to terminate their cancer drug collaboration.
- Both companies mutually decided against moving FHD-909 forward into expanded clinical trials after Phase 1 data proved underwhelming.
- An additional collaborative program focused on SMARCA2 degradation is being discontinued as well.
- To preserve capital, Foghorn is eliminating approximately 40% of its employee base.
- Management projects the biotech’s cash reserves will last through the latter half of 2029.
Shares of Foghorn Therapeutics experienced a dramatic freefall Thursday following the company’s disclosure that its collaboration with pharmaceutical giant Eli Lilly had been terminated. The stock plummeted 49% to $1.84 after trading resumed, representing the company’s largest single-session decline in its history.
Foghorn Therapeutics Inc., FHTX
Shares were temporarily halted before the announcement. Once the market reopened, a wave of selling pressure hit the stock.
The biotech firm now carries a market capitalization of approximately $212 million. This represents a significant decline for a company that previously secured a partnership with one of the pharmaceutical industry’s leading players.
Both Foghorn and Lilly mutually agreed to discontinue advancement of FHD-909 beyond its recently completed Phase 1 dose escalation study.
The experimental therapy targeted the SMARCA2 protein using an oral small molecule approach. Its mechanism relied on synthetic lethality principles, designed to exploit specific genetic vulnerabilities present in certain tumors.
The Reason Behind Program Termination
Chief Executive Adrian Gottschalk noted that the compound successfully engaged its intended target. The safety profile also appeared acceptable, even when administered at doses exceeding those predicted by preclinical studies.
However, efficacy proved insufficient. Gottschalk explained that the underlying SMARCA2/4 biological relationship failed to produce clinical results robust enough to justify continued development.
This represents a challenging conclusion following years of research investment. Additionally, Lilly’s exit encompasses more than a single development program.
Both organizations confirmed that a second oncology collaboration, centered on a Selective SMARCA2 degrader, will also be terminated. Foghorn indicated it anticipates no additional cooperative initiatives with Lilly moving forward.
The original collaboration was established in December 2021. Lilly’s Loxo Oncology division structured the agreement with $300 million in initial payments plus an $80 million equity investment at $20 per share.
Those deal terms appeared advantageous for Foghorn when announced. Current trading levels sit far below that $20 reference point.
Foghorn’s Path Forward
Following the partnership dissolution, Foghorn is implementing aggressive cost reduction measures. The organization is eliminating nearly 40% of personnel and reorganizing its operational structure.
Leadership believes these actions will extend the company’s financial runway through the second half of 2029. This timeline provides breathing room to advance its remaining development pipeline.
Foghorn plans to concentrate resources on wholly-owned proprietary programs. These include a Selective EP300 degrader, a Selective CBP degrader, and an oral therapeutic targeting immunology and inflammation.
The company intends to maintain its induced proximity technology platform as a central strategic pillar. These initiatives operate independently of Lilly financial support.
For Lilly, market reaction proved minimal. Its shares declined roughly 2%, a negligible movement for an enterprise of that scale.
For Foghorn, the implications are far more severe. The biotechnology firm now operates largely independently, relying on existing capital reserves and a significantly reduced workforce to advance its pipeline through the coming years.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
